Popular terms

Expression Vector topics
Expression Vector
Recombinant
Nucleic Acid
Antibodies
Polypeptide
Amino Acid
Amino Acid Sequence
Nucleic Acids
Polynucleotide
Nucleotide
Cytomegalovirus
Endothelial
Extracellular
Endothelial Cell
Epithelial

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Expression Vector patents



      

This page is updated frequently with new Expression Vector-related patent applications.




Date/App# patent app List of recent Expression Vector-related patents
06/23/16
20160177335 
 Recombinant protein expression using a hybrid chef1 promoter patent thumbnailnew patent Recombinant protein expression using a hybrid chef1 promoter
The invention provides expression vectors and host cells for high-level expression of recombinant proteins. The expression vectors comprise chinese hamster ovary elongation factor 1-α (chef1) transcriptional regulatory dna elements and a cytomegalovirus (cmv) promoter and/or a human adenovirus tripartite leader (adtpl) sequence.

06/23/16
20160177294 
 Random rna libraries, methods of generating same, and screening methods utilizing same patent thumbnailnew patent Random rna libraries, methods of generating same, and screening methods utilizing same
This invention provides sets and libraries of short hairpin ribonucleic acid (shrna) molecules comprising a double-stranded region of random sequence containing random mismatches, methods of generating same, sets and libraries of expression vectors for same, methods of generating same, and methods for identifying an rna therapeutic or rna molecule that has an ability to affect a biological parameter, for identifying a drug target for a disease or disorder of interest, and for identifying a variant of an rna molecule that has an altered ability to affect a biological parameter of interest.. .

06/23/16
20160177288 
 Method for producing alpha-santalene patent thumbnailnew patent Method for producing alpha-santalene
The present invention provides a method of producing α-santalene by contacting at least one polypeptide with farnesyl phyrophosphate (fpp). In particular, the method may be carried out in vitro or in vivo to produce α-santalene, a very useful compound in the fields of perfumery and flavoring.

06/23/16
20160176963 
 Antibodies to tigit patent thumbnailnew patent Antibodies to tigit
The present invention provides antibodies, or antigen binding fragments thereof, that bind to human tigit (t cell immunoreceptor with ig and itim domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the pd-1/pd-l1 interaction.

06/16/16
20160168580 
 Expression vector for cyanobacteria patent thumbnailExpression vector for cyanobacteria
The present disclosure discloses a vector that can be used for both cyanobacteria and e. Coli, which contains, sequentially, a puc replication origin as a replication origin; a spectinomycin-resistant gene as a selection marker; and a promoter selected from a group consisting of a trc promoter, a teta promoter or a modified teta promoter, a bad promoter and a cbbl promoter.
Korea Institute Of Science And Technology


06/16/16
20160168264 
 Antibodies directed to her-3 and uses thereof patent thumbnailAntibodies directed to her-3 and uses thereof
The present invention relates to binding proteins that bind to her-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided.
Amgen, Inc.


06/16/16
20160168249 
 Human monoclonal antibodies to o8e patent thumbnailHuman monoclonal antibodies to o8e
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to o8e with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E.r. Squibb & Sons, L.l.c.


06/16/16
20160168226 
 Process for production of insulin and insulin analogues patent thumbnailProcess for production of insulin and insulin analogues
A process for production of insulin or insulin analogues by expression of insulin or insulin analogues through an expression vector in a host cell is provided. The expression vector includes a leader peptide of seq id no 3; a nucleotide sequence encoding an affinity tag linked to c-terminal end or n terminal end of nucleotide sequence of the leader peptide; and a nucleotide sequence encoding for a cleavage site ligated to nucleotide sequence of the leader peptide through nucleotide sequence encoding the affinity tag..
Biogenomics Limited


06/09/16
20160160254 
 Plants expressing cell wall degrading enzymes and expression vectors patent thumbnailPlants expressing cell wall degrading enzymes and expression vectors
Vectors for expression of proteins in plants are described. The proteins may be enzymes and the enzymes can be but are not limited to cell wall degrading enzymes.
Agrivida, Inc.


06/09/16
20160159898 
 Methods of producing two chain proteins in bacteria patent thumbnailMethods of producing two chain proteins in bacteria
Provided herein are methods of producing a polypeptide containing two chains, such as an antibody including a light chain and a heavy chain. In particular, methods are provided for producing heterologous secretory proteins in bacteria through utilization of optimized expression vectors and culture processes..
Genentech, Inc.


06/09/16
20160159880 

Methods of producing two chain proteins in bacteria


Provided herein are methods of producing a recombinant polypeptide containing two chains, such as an immune mobilizing monoclonal t-cell receptor against cancer (immtac) protein including an alpha chain and a beta chain. In particular, methods are provided for producing heterologous secretory proteins in bacteria through utilization of optimized expression vectors and culture processes..
Genentech, Inc.


06/09/16
20160157500 

Bgl6 beta-glucosidase and nucleic acids encoding the same


The present invention provides a novel β-glucosidase nucleic acid sequence, designated bgl6, and the corresponding bgl6 amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding bgl6, recombinant bgl6 proteins and methods for producing the same..
Danisco Us Inc.


06/02/16
20160153023 

Biosensors that detect nad+


A polypeptide biosensor that detects free nad+ is disclosed. The polypeptide comprises a first fragment from an nad+ dependent dna ligase acetylation domain, a second fragment from the nad+ dependent dna ligase acetylation domain, and a fluorescent protein, wherein the fluorescent protein is positioned between the two dna ligase acetylation domain fragments.
Oregon Health & Science University


06/02/16
20160152732 

Antibodies directed to ricin toxin


An isolated monoclonal antibody or any antigen-binding fragment thereof which binds to ricin toxin, an expression vector including the isolated nucleic acid molecule and a host cell transfected with said isolated nucleic acid molecule or with the expression vector, a pharmaceutical composition including as an active ingredient the isolated monoclonal antibody or any antigen-binding fragment thereof, the bispecific molecule or the immunoconjugate and a pharmaceutically acceptable carrier, excipient or diluent, and a method of prophylaxis, treatment or amelioration of ricin toxin poisoning including administering to a subject in need thereof a therapeutically effective amount of the isolated monoclonal antibody or any antigen-binding fragment thereof, the bispecific molecule, the immunoconjugate or the pharmaceutical composition.. .
The Israel Institute Of Biological Research (iibr)


06/02/16
20160152681 

Anti-human papillomavirus 16 e6 t cell receptors


Disclosed is a t cell receptor (tcr) having antigenic specificity for an hla-a2-restricted epitope of human papillomavirus (hpv) 16 e6, e629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


05/26/16
20160145641 

Stepwise differentiation of stem cells for the production of eukaryotic membrane proteins


A method useful for making a eukaryotic membrane protein in vitro may be carried out by (a) propagating in vitro vertebrate stem cells; (b) transforming the vertebrate stem cells in vitro with a heterologous expression vector containing a nucleic acid encoding the eukaryotic membrane protein; and then (c) differentiating the stem cells in vitro into differentiated cells (or photoreceptor-like cells) that express the membrane protein.. .
Uab Research Foundation


05/26/16
20160145604 

An integrated system for library construction, affinity binder screening and expression thereof


A recombinant polynucleotide suitable for use in a display vector is provided. The recombinant polynucleotide includes from 5′ to 3′: a first nucleic acid sequence (or insert) encoding an amino acid sequence to be displayed on a surface; a first pre-selected restriction site; a second nucleic acid sequence encoding a surface peptide capable of being displayed on the surface; and a second pre-selected restriction site.
Adagene Inc.


05/26/16
20160145596 

Subtilase variants and polynucleotides encoding same


The present invention relates to novel subtilase variants exhibiting increased stability and preferably on par or improved wash performance. The variants of the invention are suitable for use in e.g.
Novozymes A/s


05/26/16
20160145595 

Subtilase variants and polynucleotides encoding same


The present invention relates to novel subtilase variants exhibiting increased stability and optionally on par or improved wash performance. The variants of the invention are suitable for use in e.g.
Novozymes A/s


05/26/16
20160145590 

Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor


Disclosed is a protein comprising a cytolethal distending toxin subunit b (cdtb) conjugated or fused to a bacillus anthracis toxin lethal factor (lf) or a functional portion of lf. Related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of treating or preventing cancer, and methods of inhibiting the growth of a target cell are also disclosed..
Department Of Health And Human Services


05/26/16
20160145350 

Antibodies against cd73 and uses thereof


The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human cluster of differentiation 73 (cd73) with high affinity, and inhibit the activity of cd73, and optionally mediate antibody dependent cd73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Bristol-myers Squibb Company


05/26/16
20160145338 

Human monoclonal antibodies specific for cd22


Disclosed herein are isolated human monoclonal antibodies that specifically bind human cd22 with a dissociation constant (kd) of 25 nm or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed.
The Government Of The United States Of America As Represented By The Secretary Of The Department Of


05/19/16
20160137998 

Subtilase variants and polynucleotides encoding same


The present invention relates to novel subtilase variants exhibiting increased stability and optionally on par or improved wash performance. The variants of the invention are suitable for use in e.g.
Novozymes A/s


05/19/16
20160137988 

Novel cytochrome p450 enzymes from sorghum bicolor


Two novel cytochrome p450 genes are isolated from sorghum, each gene encoding a protein having pentadecatrienyl resorcinol hydroxylase activity. Expression vectors containing these sequences are made and used to elevate levels of pentadecatrienyl resorcinol hydroxylase in transgenic cells and organisms..
The United States Of America, As Represented By The Secretary Of Agriculture


05/19/16
20160137722 

Humanized monoclonal antibodies that specifically bind and/or neutralize japanese encephalitis virus (jev) and their use


Disclosed herein are isolated humanized monoclonal antibodies that specifically bind japanese encephalitis virus (jev) with a binding affinity of about 1.0 nm or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed.
The United States Of America, As Represented By The Secretary, Department Of Health And Human


05/19/16
20160137720 

Method for refining protein including self-cutting cassette and use thereof


The present invention relates to a self-cleaving fusion protein including a target protein, a peptide consisting of amino acid sequence represented by lpxtg, a domain of sortase a having cleaving function, and a tag, which are sequentially positioned from the amino terminal; a nucleic acid encoding the same; an expression vector including the nucleic acid of the present invention; and a cell transformed with the expression vector of the present invention. In addition, the present invention relates to a method for refining a target protein including culturing, dissolving, and purifying the transformed cell, and a method for preparing a therapeutic antibody-drug conjugate by using the purifying method..
Scripps Korea Antibody Institute


05/19/16
20160137697 

Cosmetic composition for improving skin conditions comprising fusion protein


The present invention relates to a fusion protein comprising a skin-penetrating peptide, a polynucleotide encoding the fusion protein, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the fusion protein, a cosmetic composition for improving skin conditions, which comprises the fusion protein, and a pharmaceutical composition for external skin use, which comprises the fusion protein. The fusion protein of the invention comprises a skin-penetrating peptide bound to a physiologically active protein.
Lg Household & Health Care Ltd.


05/19/16
20160136299 

Glycoengineered antibody drug conjugates


The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides.
Genzyme Corporation


05/12/16
20160130350 

Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation


Methods for preventing or inhibiting inflammation in a subject are disclosed. In one aspect, the method comprises administering to a subject diagnosed with an inflammatory disease an effective amount of an anti-inflammatory agent that (1) inhibits the expression of cxcl9, cxcl10, cxcl11, cxcl13, cxcr3 and/or cxcr5, or (2) inhibits the interaction between cxcr3 and cxcl9, cxcl10 or cxcl11, or between cxcr5 and cxcl13, or (3) inhibits a biological activity of cxcl9, cxcl10, cxcl11, cxcl13, cxcr3 and/or cxcr5, wherein the agent comprises an antibody, antibody fragment, short interfering rna (sirna), aptamer, synbody, binding agent, peptide, aptamer-sirna chimera, single stranded antisense oligonucleotide, triplex forming oligonucleotide, ribozyme, external guide sequence, or an agent-encoding expression vector..
Jyant Technologies, Inc.


05/12/16
20160130332 

Antibodies to human signal peptide-containing proteins


The invention provides a human signal peptide-containing proteins (sigp) and polynucleotides which identify and encode sigp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Incyte Corporation


05/05/16
20160122778 

Stress tolerant plants and methods thereof


The present invention provides a method and dna molecules that when expressed in a plant produces transgenic plants with improved abiotic stress tolerance. The invention includes plant expression vectors comprising the dna molecules, and plants containing such dna molecules..
Monsanto Technology Llc


05/05/16
20160122730 

Novel molecules of the card-related protein family and uses thereof


Novel card-9, card-10, or card-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated card-9, card-10, or card-11 proteins, the invention further provides card-9, card-10, or card-11, fusion proteins, antigenic peptides and anti-card-9, card-10, or card-11 antibodies.
Millennium Pharmaceuticals, Inc.


05/05/16
20160122724 

Recombinant baculovirus expression vector and cell


A recombinant baculovirus expression vector or cell comprising an engineered baculovirus fp25k gene with one to three modified or mutated spots, the modified spots comprise the two 7-adenine mononucleotide repeats (mnr) and the 10th ttaa site. The invention also provides the method of making the vector and baculovirus..
Miami University


05/05/16
20160122413 

Method for producing antibody using "naked" expression vector expressing type ii transmembrane fusion protein


Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector may be useful in generating an antibody directed to an antigen, comprising a gene in operable linkage with a promoter, which gene encodes upon expressing a fusion protein comprising (i) cd134l, a fragment, homologous or orthologues protein thereof as n-terminal moiety of the fusion protein; and (ii) all or part of an antigenic protein as c-terminal moiety of the fusion protein.
Delphi Genetics Sa


05/05/16
20160122402 

Retro polypeptides for activation immunity to cancer and viral infection


A polypeptide that drives t cell proliferation and differentiation, and methods and agents for modulating the expression and/or function of the polypeptide. Agents that up regulate the expression and/or function of the polypeptide are useful in the treatment or prevention of diseases and disorders that would benefit from stimulation of t cell proliferation and/or differentiation, such as cancer and chronic viral infections.
Imperial Innovations Limited


04/14/16
20160102136 

Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use


Isolated vhh monoclonal antibodies are disclosed that specifically bind to a norovirus polypeptide. In some embodiments, the norovirus is a genogroup i norovirus or a genogroup ii norovirus.

04/14/16
20160102133 

Mutant factor viii compositions and methods


In one aspect, present invention provides a recombinant mutant human factor viii having increased expression and/or secretion as compared to wild-type factor viii. In certain embodiments, the recombinant factor viii includes one or more amino acid substitution(s) selected from the group consisting of i86, y105, a108, d115, q117, f129, g132, h134, m147 and l152.

04/14/16
20160102128 

Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells


The present invention further provides expression vectors, and il-15 and il-15 receptor alpha combinations (nucleic acid and protein) that increase il-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of il-15 after dna, rna or protein administration in a subject (e.g.

04/14/16
20160102125 

Expression systems and associated methods


A method of producing synthetic spider silk, including: transforming escherichia coli with an expression vector; fermenting the transformed e. Coli in a culture medium; inducing spider silk protein expression in the cultured e.

04/07/16
20160097053 

Yeast promoters from pichia pastoris


In accordance with the invention, isolated nucleic acids, expression methods, host cells, expression vectors, and dna constructs for producing proteins, and proteins produced using the expression methods are described. More particularly, nucleic acids isolated from pichia pastoris wherein the nucleic acids have promoter activity are described.
Keck Graduate Institute Of Applied Life Sciences


04/07/16
20160096875 

Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells


The present invention further provides expression vectors, and il-15 and il-15 receptor alpha combinations (nucleic acid and protein) that increase il-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of il-15 after dna, rna or protein administration in a subject (e.g.

04/07/16
20160095919 

Therapeutic agent for neurological disorder


Provided is a therapeutic agent for a neurological disorder directly acting on oxygen concentration-dependent vascular barrier breakdown. The therapeutic agent for a neurological disorder contains any one of (a) a functional nucleic acid against adam (a disintegrin and metalloproteinase)12 or adam17, (b) a functional nucleic acid expression vector containing a dna encoding the functional nucleic acid (a) and (c) a neutralizing antibody against adam12 or adam17, as an active ingredient.
Yamaguchi University


03/31/16
20160089432 

Methods and compositions for inducing protective immunity against human immunodeficiency virus infection


Compositions, vaccines and methods for inducing protective immunity against human immunodeficiency virus (hiv) infection are described. Heterologous vaccine combinations of one or more viral expression vectors and an isolated antigenic polypeptide induced strong protective immunity against infections by one or multiple clades of hiv..
Crucell Holland B.v.


03/17/16
20160076051 

Expression process


A process for the production of a target polypeptide is provided. The process comprises expression of an expression vector for expressing a target polypeptide in a host cell, preferably a mammalian cell, the expression vector comprising an expression cassette comprising a polynucleotide encoding a recombinant polypeptide operably linked to a fibronectin secretion leader sequence; and recovering the target polypeptide..
Fujifilm Diosynth Biotechnologies Uk Limited


03/17/16
20160075797 

Anti-vasa antibodies, and methods of production and use thereof


Anti-vasa antibodies (mabs), particularly humanized mabs that specifically bind to vasa with high affinity, are disclosed. The amino acid sequences of the cdrs of the light chains and the heavy chains, as well as consensus sequences for these cdrs, of these anti-vasa mabs are provided.
Ovascience, Inc.


03/17/16
20160075782 

Human monoclonal antibodies to programmed death ligand 1 (pd-l1)


The present disclosure provides isolated monoclonal antibodies particularly human monoclonal antibodies that specifically bind to pd-l1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E.r. Squibb & Sons, L. L. C.


03/10/16
20160068856 

Fungal resistant plants expressing mybtf


The present invention relates to a method of increasing resistance against fungal pathogens of the order pucciniales in plants and/or plant cells. This is achieved by increasing the expression of a mybtf protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh


03/10/16
20160068849 

Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy


Methods are provided for the synthesis and secretion of recombinant hetero-multimeric proteins in mating competent yeast. A first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell.
Alderbio Holdings Llc


03/03/16
20160060639 

Positive-selection cloning and expression vector based on the toxicity of killin


Here we report the creation of a new positive-selection cloning vector dubbed pkillin, which overcomes all of the above pitfalls. The essence behind its high cloning efficiency is the extreme toxicity and small size of the toxic domain of killin, a recently discovered p53 target gene.

03/03/16
20160060354 

Site-specific glycoengineering of targeting moieties


The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides.
Genzyme Corporation


03/03/16
20160058852 

Immunotherapy of cancer through combination of local and systemic immune stimulation


Provided herein are compositions and methods for immunotherapy of cancers, said methods combining systemic vaccination with a recombinant expression vector encoding a viral antigen and/or a cancer specific tumor antigen(s) to induce activated cd8 t-cells, with a local (e.g., intratumoral) immune stimulation using standard or modified application of a tlr agonist, to induce local inflammatory and innate immune responses which recruit t-cells to the tumor.. .
Immune Design Corp.


02/25/16
20160053017 

Anti-cd276 polypeptides, proteins, and chimeric antigen receptors


Polypeptides and proteins that specifically bind to and immunologically recognize cd276 are disclosed. Chimeric antigen receptors (cars), anti-cd276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed.
Biomed Valley Discoveries, Inc.


02/25/16
20160051658 

Neisserial antigenic peptides


This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria neisseria meningitidis b. Also provided are nucleic acids encoding for such proteins, polypeptides, and/or fragments, as well as nucleic acids complementary thereto e.g., antisense nucleic acids).
Glaxosmithkline Biologicals Sa


02/18/16
20160046957 

Production of fully processed and functional factor x in a furin-secreting mammalian expression system


Disclosed herein are methods for production of fully-processed mature factor x in an expression system producing a controlled amount of furin between 50 u/ml and 300 u/ml of culture supernatant. Also disclosed are transformed cells, expression systems, and expression vectors for the expression of furin and factor x..
Baxalta Gmbh


02/18/16
20160046921 

Enzymatic methods and enzymes


Provided are methods to identify modulators and in particular inhibitors of body malodour formation employing peptidase enzymes, the peptidase enzymes and corresponding nucleotide sequences, expression vectors, transfected host cells, methods of forming the peptidase enzymes and methods to prevent body malodour.. .
Givaudan Sa


02/18/16
20160046701 

Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy


The present invention is based, in part, on our discovery that targeting epitopes within one or more of the ec2-ec5 subdomains of e-cadherin results in the death of epithelial-derived tumor cells but not in the death of normal, healthy epithelial cells or non-epithelial cells including endothelial cells and fibroblasts. Accordingly, the compositions of the invention include polypeptides having an amino acid sequence of one or more of the ec2-ec5 subdomains of e-cadherin and biologically active variants thereof; expression vectors and cells for expressing such polypeptides; and agents (e.g., antibodies) that target the ec2-ec5 subdomains.
The Research Foundation For The State University Of New York


02/18/16
20160046694 

Methods and constructs for expressing biologically active proteins in mammalian cells


Methods and constructs for expressing biologically active proteins in eukaryotic cells are disclosed. A method for producing a non-conventional expression vector for production of biologically active compounds comprising a primary transcriptional unit and one or more secondary transcriptional units, a primary transcriptional unit encoding promoter, synthetic intron, selectable marker gene and polyadenylation signal or transcriptional terminator and a second transcriptional unit encoding promoter and polypeptide of interest surrounded by insulator sequences and placed in the intron of primary transcriptional unit.
Usha Biotech Limited


02/18/16
20160046691 

Novel epitope for switching to th2 cell and use thereof


The present invention relates to a novel epitope to convert t cell to type 2 helper t (th2) cell. Specifically, the present invention relates to an epitope constituting the 20th to 30th amino acids (seq id no.2) of extracellular domain (ecd) of activation-inducible tumor necrosis factor receptor (aitr), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting t cell to th2 cell and a method of conversion, a pharmaceutical composition comprising the antibody for preventing or treating autoimmune disease, and a method for treating autoimmune disease using the antibody..

02/18/16
20160046677 

Pseudomonas exotoxin a with less immunogenic b cell epitopes


The invention provides a pseudomonas exotoxin a (pe) comprising an amino acid sequence having a substitution of one or more of amino acid residues e420, d463, y481, l516, r563, d581, d589, and k606, wherein the amino acid residues are defined by reference to seq id no: 1. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


02/11/16
20160040185 

Expression vector and preparing a polypeptide of interest using the same


A fusion polynucleotide including a human cmv promoter and an intron, a recombinant vector including the fusion polynucleotide and a gene encoding a polypeptide of interest, a recombinant cell comprising the recombinant vector, and a method of producing a polypeptide of interest using the recombinant vector or recombinant cell.. .
Samsung Electronics Co., Ltd.


02/11/16
20160040184 

Phi-4 polypeptides and methods for their use


Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein.
Pioneer Hi-bred International, Inc.


02/11/16
20160040182 

Fungal resistant plants expressing hcp5


The present invention relates to a method of increasing resistance against fungal pathogens of the order pucciniales, preferably the family phacopsoraceae, in plants and/or plant cells. This is achieved by increasing the expression of an hcp5 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh


02/11/16
20160040173 

Light-switchable gene expression system and the methods for controlling gene expression in prokaryotic bacterium


Provided is an optically controlled gene expression system of prokaryotic bacterium, comprising: a) a photosensitive recombinant transcription factor encoding gene, the photosensitive recombinant transcription factor is one fusion protein comprising a first polypeptide as the dna bonding domain and a second polypeptide as the photosensitive domain; b) a target transcription unit comprising promoter or promoter-reaction element or reaction element-promoter containing at least one reaction element recognized/bound by the first polypeptide and the nucleic acid sequence to be transcribed. Also provided is a prokaryotic expression vector comprising said optically controlled gene expression system, and a method for regulating gene expression in a prokaryotic host cell by using the optically controlled gene expression system.
East China University Of Science And Technology


02/11/16
20160040157 

Multi-chain eukaryotic display vectors and uses thereof


A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin fab fragments.
Dyax Corp.


02/11/16
20160039933 

Antibodies specific to cadherin-17


The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to cadherin-17 with high affinity. Nucleic acid molecules encoding cadherin-17 antibodies, expression vectors, host cells and methods for expressing the cadherin-17 antibodies are also provided.
Oxford Biotherapeutics Limited


02/11/16
20160039908 

Method and pharmaceutical composition for use in the treatment of cancer


The present invention relates to a soluble peptide comprising the amino acids sequence: krfyvvmwkk (seq id no: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier..
Assistance Publique-hopitaux De Paris


02/11/16
20160038578 

Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof


Disclosed herein are isolated human monoclonal antibodies, and functional fragments thereof, that specifically bind hmw-maa. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


02/11/16
20160038576 

Immunogenic compositions for inducing an immune response for elimination of senescent cells


Provided herein are immunogenic compositions (vaccines) and methods for immunizing a subject with the immunogenic compositions for inducing an adaptive immune response directed specifically against senescent cells for treatment and prophylaxis of age-related diseases and disorders, and other diseases and disorders associated with or exacerbated by the presence of senescent cells. The immunogenic compositions provided herein comprise at least one or more senescent cell-associated antigens, polynucleotides encoding senescent cell-associated antigens, and recombinant expression vectors comprising the polynucleotides for use in administering to a subject in need thereof..
Buck Institute For Research On Aging


02/04/16
20160032283 

Random rnai libraries, methods of generating same, and screening methods utilizing same


This invention provides expression vectors for a ribonucleic acid (rna) molecule comprising a double-stranded region of random sequence, sets and libraries of same, methods of generating same, and methods for identifying an rna therapeutic or rna molecule that has an ability to affect a biological parameter, for identifying a drug target for a disease or disorder of interest, and for identifying a variant of an rna molecule that has an altered ability to affect a biological parameter of interest.. .
The Trustees Of The University Of Pennsylvania


02/04/16
20160032279 

Polypeptide display libraries and methods of making and using thereof


Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand.
The Regents Of The University Of California


02/04/16
20160032256 

Cytochrome p450s and uses thereof


The invention features isolated cytochrome p450 polypeptides and nucleic acid molecules, as well as expression vectors and transgenic plants containing these molecules. In addition, the invention features uses of such molecules in methods of increasing the level of resistance against a disease caused by a plant pathogen in a transgenic plant, in methods for producing altered compounds, for example, hydroxylated compounds, and in methods of producing isoprenoid compounds..
University Of Kentucky Research Foundation


02/04/16
20160031949 

Novel insecticidal proteins and methods of use


Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein.
Pioneer Hi-bred International, Inc.


02/04/16
20160030597 

S100b mini-promoters


Isolated polynucleotides comprising a s100b mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
The University Of British Columbia


01/28/16
20160024600 

Coincidence reporter gene system


Disclosed is a nucleic acid comprising a nucleotide sequence encoding (i) two or more reporters comprising a first reporter and a second reporter that is different from the first reporter; and (ii) one or more ribosomal skip sequences, wherein a ribosomal skip sequence is positioned between the first and second reporters, wherein the first and second reporters are stoichiometrically co-expressed from the nucleotide sequence and the nucleic acid does not comprise a cytomegalovirus-immediate early (cmv-ie) promoter. Also disclosed are methods of screening test compounds for ability to modulate a biological activity of interest using the nucleic acid, as well as related recombinant expression vectors, host cells, and populations of cells..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser


01/28/16
20160024530 

Cytochrome p450s and uses thereof


The invention features isolated cytochrome p450 polypeptides and nucleic acid molecules, as well as expression vectors and transgenic plants containing these molecules. In addition, the invention features uses of such molecules in methods of increasing the level of resistance against a disease caused by a plant pathogen in a transgenic plant, in methods for producing altered compounds, for example, hydroxylated compounds, and in methods of producing isoprenoid compounds..
University Of Kentucky Research Foundation


01/28/16
20160024511 

Yeast promoters for protein expression


Isolated nucleic acids, expression methods, host cells, expression vectors, and dna constructs for producing proteins, and proteins produced using the expression methods are disclosed. More specifically, nucleic acids isolated from pichia pastoris having promoter activity and expression methods, host cells, expression vectors, and dna constructs of using the pichia pastoris promoters to produce different proteins and polypeptides are disclosed..
Biogrammatics, Inc.


01/28/16
20160024509 

Expression vector


An expression vector for expressing a target polypeptide in a prokaryotic cell is provided. The vector comprises a promoter operably linked to a polynucleotide encoding the target polypeptide operably linked to a eukaryotic secretion leader sequence, the eukaryotic secretion leader sequence encoding a signal peptide sequence selected from the group consisting of: a) mlkrsswlatlglltvasvstivya; b) mkkatfitcllavllvsnpiwna; c) mkvsaaalaviliatalcapasa; d) mkvstaflcllltvsafsaqvla; and e) mkclllalglalacaaqa.
Fujifilm Diosynth Biotechnologies Uk Limited


01/28/16
20160024221 

Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies


The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to fucosyl-gm1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E. R. Squibb & Sons, L.l.c.


01/28/16
20160024177 

Novel epitope for switching to th1 cell and use thereof


The present invention relates to a novel epitope that converts t cell to type 1 helper t (th1) cell. Specifically, the present invention relates to an epitope constituting the 56th to 65th amino acids (seq id no.2) of extracellular domain (ecd) of activation-inducible tumor necrosis factor receptor (aitr), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting t cell to th1 cell and a method for converting t cell to th1 cell, a pharmaceutical composition comprising the antibody for preventing or treating cancer, a method for treating cancer using the antibody, a composition comprising the antibody for enhancing immunity, and a method for enhancing immunity using the antibody..

01/28/16
20160024174 

Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen


Provided are compositions and methods for prophylaxis and/or therapy of a variety of cancers which express a ny-eso-1 antigen. Included are recombinant t cell receptors (tcrs), polynucleotides encoding them, expression vectors that include the polynucleotides, and cells into which the polynucleotides have been introduced to produce modified cells, including cd4+ t cells, cd8+ t cells, natural killer t cells, γδ t cells, and progenitor cells, such as haematopoietic stem cells.
Health Research, Inc.


01/28/16
20160024159 

Potent and selective inhibitors of nav1.7


Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of nav1.7.
Amgen Inc.


01/28/16
20160022807 

Methods and compositions for in vivo immune stimulation and antigen production


Disclosed are compositions and methods comprising a vector and a reverse genetics competent unit. The vector may comprise baculovirus expression vectors, bacmids, vaccinia virus and synthetic vectors and the reverse genetics competent unit may comprise pathogenic units necessary for producing pathogens de novo from a nucleotide-based vector.
University Of Maryland


01/21/16
20160017297 

Recombinant manganese oxidase


Disclosed herein is a recombinant bacillus manganese oxidase complex, including a bacterial expression vector for the expression of the complex and a method of synthesizing the complex.. .
Oregon Health & Science University


01/21/16
20160017289 

Tgif2-induced reprogramming of hepatic cells to pancreatic progenitor cells and medical uses thereof


Disclosed are genetically modified human pancreatic progenitor cells, comprising an exogenous nucleic acid molecule encoding tgif2, for use as a medicament in the treatment of a subject with diabetes, in addition to methods for the production of said cells. Also disclosed is an expression vector encoding tgif2 for use as a medicament in the treatment of a subject with diabetes..
Max-delbrueck-centrum Fuer Molekulare Medizin


01/21/16
20160017281 

Cell expression system


An expression system for expressing a protein comprising: a eukaryotic host cell carrying a dihydrofolate reductase (dhfr) deficiency; and an expression vector, the expression vector encoding the human growth hormone gene; a expression vector, the expression vector comprising: a eukaryotic selectable marker including a minimal sv 40 early promoter driving expression of a sequence encoding dihydrofolate reductase for complementing the dhfr deficiency in the host cell; a prokaryotic selectable marker conveying ampicillin resistance to a prokaryotic host cell; a prokaryotic origin of replication; a plurality of multiple cloning sites (mcs); and at least one protein expression module comprising: a simian vacuolating virus 40 (sv40) early promoter, inclusive of its 72 bp enhancer repeats; and a rabbit β-globin intron sequence being separable from a sv40 p a sequence by a first multiple cloning site, for receiving a coding sequence and expressing a desired protein therefrom.. .
Neuclone Biologies Pty Ltd


01/21/16
20160017277 

Cell culture media composition and methods of producing thereof


A serum free cell culture media, wherein the media is adapted to be conditioned by culturing a first set of eukaryotic cells in the media, wherein the first set of eukaryotic cells use an expression vector to excrete levels of desired complex proteins into the media; wherein said desired complex proteins include human growth hormone (hgh), growth hormone-like growth factors, insulin-like growth factors, insulin, modified insulins, cytokines, mitogenic proteases and mixtures thereof; and wherein the media is adapted to grow a set of eukaryotic cells.. .
Neuclone Biologics Pty Ltd


01/21/16
20160017017 

Growth hormone compounds


The invention relates to growth hormone compounds with a long plasma half-life obtained by fc linkage. An increased half-life is an advantage allowing a less frequent or low dosage administration of therapeutic.
Novo Nordisk Healthcare Ag


01/21/16
20160017012 

Delivery of card protein as therapy for occular inflammation


The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. In an exemplary embodiment, a method is disclosed that involves administering an expression vector that delivers a secretable and cell penetrating card to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization..
University Of Florida Research Foundation, Inc.


01/21/16
20160015062 

Feline bitter taste receptors and methods


A family of novel feline bitter taste receptors, referred to as feline tas2r (ftas2r), are disclosed herein. Isolated polynucleotides encoding the novel feline bitter taste receptors and chimeric polypeptides are also disclosed, as are expression vectors and host cells for expression of the novel feline bitter taste receptors.
Applied Food Biotechnology, Inc.


01/21/16
20160015010 

Animal model of charcot-marie-tooth disease as hsp27 mutant (s135f) carrier


The present invention relates to a hsp27 mutation (s135f) mediated charcot-marie-tooth disease (cmt) animal model. Particularly, the vector expressing mutant hsp27 protein wherein the 135th serine is substituted with phenylalanine has been injected in the mouse zygote and then the mouse harboring the expression vector was selected.
Samsung Life Public Welfare Foundation


01/14/16
20160009788 

Monoclonal antibodies that neutralize a norovirus


Monoclonal neutralizing antibodies are disclosed that specifically bind to a norovirus. In some embodiments, the norovirus is a genogroup ii norovirus or a genogroup ii norovirus.
The United States Of America, As Represented By The Secretary, Department Of Health And Human


01/14/16
20160009779 

Novel fusion tags and expression vector system for the expression of human parathyroid hormone (rhpth)


The present invention provides for fusion tags of 20 to 50 amino acids having a sequence as given in fig. 1, fusion tags sharing homology with these fusion tags, or hybrid fusion tags comprising sequences of fig.
Alkem Laboratories Ltd.


01/07/16
20160003852 

Feline bitter taste receptors and methods


A family of novel feline bitter taste receptors, referred to as feline tas2r (ftas2r), are disclosed herein. Isolated polynucleotides encoding the novel feline bitter taste receptors and chimeric polypeptides are also disclosed, as are expression vectors and host cells for expression of the novel feline bitter taste receptors.
Applied Food Biotechnology, Inc.


01/07/16
20160002682 

In vivo and in vitro olefin cyclopropanation catalyzed by heme enzymes


The present invention provides methods for catalyzing the conversion of an olefin to any compound containing one or more cyclopropane functional groups using heme enzymes. In certain aspects, the present invention provides a method for producing a cyclopropanation product comprising providing an olefinic substrate, a diazo reagent, and a heme enzyme; and admixing the components in a reaction for a time sufficient to produce a cyclopropanation product.
California Institute Of Technology


01/07/16
20160002668 

Compositions and methods of use thereof for identifying anti-viral agents


The present disclosure provides a recombinant expression vector comprising a nucleotide sequence encoding a herpesvirus transactivator, where the nucleotide sequence is operably linked to a herpesvirus control element. The present disclosure provides cell lines genetically modified to express a herpesvirus transactivator under the control of a herpesvirus control element.
The J. David Gladstone Institutes


01/07/16
20160002666 

Methods and compositions for treating genetically linked diseases of the eye


Expression vectors and therapeutic methods of using such vectors in the treatment of diseases of the eye resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye.. .
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services


01/07/16
20160002354 

Antibodies to bone marrow stromal antigen 1


The invention provides antibodies which bind to the adp-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided.
Oxford Biotherapeutics Ltd




Expression Vector topics: Expression Vector, Recombinant, Nucleic Acid, Antibodies, Polypeptide, Amino Acid, Amino Acid Sequence, Nucleic Acids, Polynucleotide, Nucleotide, Cytomegalovirus, Endothelial, Extracellular, Endothelial Cell, Epithelial

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Expression Vector for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Expression Vector with additional patents listed. Browse our RSS directory or Search for other possible listings.


2.5854

5368

469398 - 0 - 101